Brokers Set Expectations for PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Cantor Fitzgerald issued their FY2025 earnings estimates for Palvella Therapeutics in a research note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($2.60) per share for the year. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($3.40) by $2.66.

Several other equities analysts have also weighed in on the stock. Canaccord Genuity Group cut their price objective on shares of Palvella Therapeutics from $53.00 to $52.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Stifel Nicolaus began coverage on shares of Palvella Therapeutics in a research note on Wednesday, March 26th. They issued a “buy” rating and a $45.00 target price for the company. Jones Trading began coverage on shares of Palvella Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $45.00 target price for the company. TD Cowen began coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price for the company. Finally, Chardan Capital began coverage on shares of Palvella Therapeutics in a research note on Wednesday, April 9th. They issued a “buy” rating and a $50.00 target price for the company. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $46.29.

Palvella Therapeutics Price Performance

Shares of NASDAQ PVLA opened at $23.00 on Wednesday. The firm has a 50 day simple moving average of $24.31. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $29.27. The firm has a market capitalization of $253.99 million, a price-to-earnings ratio of -1.90 and a beta of 0.10.

Insider Transactions at Palvella Therapeutics

In related news, Director George M. Jenkins acquired 2,500 shares of the stock in a transaction dated Wednesday, April 9th. The stock was bought at an average price of $20.13 per share, with a total value of $50,325.00. Following the completion of the transaction, the director now directly owns 183,171 shares of the company’s stock, valued at approximately $3,687,232.23. The trade was a 1.38% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Several large investors have recently made changes to their positions in PVLA. Suvretta Capital Management LLC acquired a new position in Palvella Therapeutics during the fourth quarter worth $8,574,000. BVF Inc. IL acquired a new position in Palvella Therapeutics during the fourth quarter worth $8,359,000. Frazier Life Sciences Management L.P. boosted its holdings in Palvella Therapeutics by 5.5% during the first quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock worth $19,313,000 after purchasing an additional 36,120 shares during the last quarter. Samsara BioCapital LLC acquired a new position in Palvella Therapeutics during the fourth quarter worth $8,154,000. Finally, Adams Street Partners LLC acquired a new position in Palvella Therapeutics during the fourth quarter worth $4,916,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.